Bone Health Impairment in Patients with Hemoglobinopathies: From Biological Bases to New Possible Therapeutic Strategies
International Journal of Molecular Sciences · 01.03.2024 · 25 (5) · 2902
DOI: 10.3390/ijms25052902 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 01.03.2024. Verfasst von Alessandra Di Paola und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Woman, Child and General and Specialist Surgery, University of Campania "Luigi Vanvitelli", 80138 Naples, Italy. Hauptthemen laut MEDLINE: Hemoglobinopathies, Anemia, Sickle Cell, Thalassemia, beta-Thalassemia. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 151 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Hemoglobinopathies are monogenic disorders affecting hemoglobin synthesis. Thalassemia and sickle cell disease (SCD) are considered the two major hemoglobinopathies. Thalassemia is a genetic disorder and one of the major hemoglobinopathies determined by an impairment of globin chain production, which causes an alteration of erythropoiesis, an improvement in hemolysis, and an alteration of iron homoeostasis. In SCD, the mutations are on the β-globin chain of hemoglobin which results in a substitution of glutamic acid by valine with consequent formation of Hemoglobin S (HbS). Several factors are involved in bone metabolism alteration in patients with hemoglobinopathies, among them hormonal deficiency, bone marrow hyperplasia, iron overload, inflammation, and increased bone turnover. Bone metabolism is the result of balance maintenance between bone deposition and bone resorption, by osteoblasts (OBs) and osteoclasts (OCs). An impairment of this balance is responsible for the onset of bone diseases, such as osteoporosis (OP). Therefore, here we will discuss the alteration of bone metabolism in patients with hemoglobinopathies and the possible therapeutic strategies to contain and/or counteract bone health impairment in these patients, taking into consideration not only the pharmacological treatments already used in the clinical armamentarium, but also the new possible therapeutic strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Woman, Child and General and Specialist Surgery, University of Campania "Luigi Vanvitelli", 80138 Naples, Italy.
- Department of Experimental Medicine, University of Campania "Luigi Vanvitelli", 80138 Naples, Italy.
ORCID-Profile: Maria Maddalena Marrapodi, Deeksha Rana, Shakeel Ahmed, Domenico Roberti
Zitieren
APA
Di Paola, A., Marrapodi, M. M., Di Martino, M., Giliberti, G., Di Feo, G., Rana, D., Ahmed, S., Argenziano, M., Rossi, F., & Roberti, D. (2024). Bone Health Impairment in Patients with Hemoglobinopathies: From Biological Bases to New Possible Therapeutic Strategies. International Journal of Molecular Sciences, 25(5), 2902. https://doi.org/10.3390/ijms25052902
Vancouver
Di Paola A, Marrapodi MM, Di Martino M, Giliberti G, Di Feo G, Rana D, et al. Bone Health Impairment in Patients with Hemoglobinopathies: From Biological Bases to New Possible Therapeutic Strategies. International Journal of Molecular Sciences. 2024;25(5):2902. doi:10.3390/ijms25052902
BibTeX
@article{DiPaola2024,
author = {Di Paola, Alessandra and Marrapodi, Maria Maddalena and Di Martino, Martina and Giliberti, Giulia and Di Feo, Giuseppe and Rana, Deeksha and Ahmed, Shakeel and Argenziano, Maura and Rossi, Francesca and Roberti, Domenico},
title = {Bone Health Impairment in Patients with Hemoglobinopathies: From Biological Bases to New Possible Therapeutic Strategies},
journal = {International Journal of Molecular Sciences},
year = {2024},
volume = {25},
number = {5},
pages = {2902},
doi = {10.3390/ijms25052902}
}
EUVIMED